Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Trial With TMC278 25 mg q.d. in Combination With a Background Regimen Containing 2 N(t)RTI's in HIV-1 Infected Subjects Who Participated in TMC278 Clinical Trials and Were Still Benefitting From Treatment With TMC278

NCT01266902 is registered in ClinicalTrials.gov with Janssen R&D Ireland as lead sponsor.

NCT NCT01266902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01266902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Trial With TMC278 25 mg q.d. in Combination With a Background Regimen Containing 2 N(t)RTI's in HIV-1 Infected Subjects Who Participated in TMC278 Clinical Trials and Were Still Benefitting From Treatment With TMC278
Lead sponsor
Janssen R&D Ireland
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2011
Completion date
February 29, 2020
Enrollment
482 (actual)
Sites
98

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1 infection